GlassScriptPhysician profile
Grace Little Engle
NPI 1508328238
$4,759.38
in general payments reported to CMS, 2019-2025
29 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $648 · 2023: $1,071 · 2024: $1,636 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,002.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $666.47 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Idorsia Pharmaceuticals US INC | $459.96 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $428.66 | 2021-2025 | Breztri, Lokelma, Farxiga |
| Pfizer INC. | $378.89 | 2024-2025 | |
| Abbott Laboratories | $336.04 | 2023-2024 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Boston Scientific Corporation | $256.19 | 2022-2025 | Watchman Flx, Watchman Access System |
| Alnylam Pharmaceuticals INC. | $224.63 | 2024-2025 | Onpattro |
| Amgen INC. | $217.41 | 2023-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $184.32 | 2022-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $164.34 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $156.09 | 2023-2024 | |
| Heartflow, INC. | $147.62 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $136.76 | 2025 | |
| Astellas Pharma US INC | $122.09 | 2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $121.76 | 2023 | Abilify Asimtufii, Abilify Maintena |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $120.01 | 2023 | Uplizna |
| Corcept Therapeutics | $101.68 | 2023 | Korlym |
| Abbvie INC. | $99.76 | 2022 | |
| Philips North America LLC | $83.79 | 2025 | Ecc Solutions, Mcot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.55 | 2024-2025 | Jardiance |
| Daiichi Sankyo INC. | $68.06 | 2024 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $55.38 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $39.62 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $23.06 | 2024 | Evkeeza |
| Bridgebio Pharma, INC. | $22.67 | 2025 | Attruby |
| United Therapeutics Corporation | $18.78 | 2024 | Tyvaso |
| Altathera Pharmaceuticals LLC | $15.51 | 2024 | Sotalol Hydrochloride |
| Janssen Pharmaceuticals, INC | $14.17 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $13.11 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Engle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.